<DOC>
	<DOCNO>NCT00003134</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient recurrent glioma .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Recurrent Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy irinotecan treatment patient recurrent glioma . II . Assess toxicity irinotecan patient . III . Correlate pharmacological parameter toxicity response therapy . OUTLINE : This two arm study . Patients stratify accord prior nitrosourea administration . Patients assign 1 2 arm , 1 arm open time . Patients assign arm I receive irinotecan IV 90 minute day 1 , 8 , 15 , 22 . This follow 2 week rest continue maximum 6 course . Patients assign arm II receive irinotecan day 1 every 3 week 12 course . Patients arm receive prior nitrosoureas receive reduce start dos irinotecan . The dosage may increase per patient first course toxic effect acceptable . Arm I close 10/98 , Arm II open 10/98 . Patients follow every 3 month first year , every 6 month next 4 year , annually death .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove primary brain glioma Astrocytoma Gliosarcoma Oligodendroglioma Oligoastrocytoma Tumor progression CT scan MRI follow radiotherapy Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time upper limit normal No prior Gilbert 's syndrome Renal : Creatinine great 2.0 mg/dL Cardiovascular : No history myocardial infarction within 6 month No congestive heart failure require therapy Other : No concurrent active second malignancy No uncontrolled infection No severe concurrent disease Not pregnant lactate Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 1 prior adjuvant chemotherapy regimen 1 recurrence ( Gliadel consider 1 regimen ) At least 4 week since prior chemotherapy At least 6 week since prior nitrosoureas No prior irinotecan , topotecan , aminocamptothecin Endocrine therapy : At least 2 week fix dose corticosteroid ( corticosteroid ) prior baseline scan Radiotherapy : At least 8 week since prior radiotherapy Surgery : No surgical resection last radiotherapy chemotherapy study therapy , unless unequivocal tumor growth since surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>